-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $230

Benzinga·04/22/2026 13:26:51
Listen to the news
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $225 to $230.